CN111163799A - 用于异源repRNA免疫接种的方法和组合物 - Google Patents

用于异源repRNA免疫接种的方法和组合物 Download PDF

Info

Publication number
CN111163799A
CN111163799A CN201880063070.8A CN201880063070A CN111163799A CN 111163799 A CN111163799 A CN 111163799A CN 201880063070 A CN201880063070 A CN 201880063070A CN 111163799 A CN111163799 A CN 111163799A
Authority
CN
China
Prior art keywords
composition
antigenic protein
reprna
ivt
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880063070.8A
Other languages
English (en)
Chinese (zh)
Inventor
R·福格尔斯
M·范德内特科夫舍坦
D·J·欧文
R·魏斯
E·B·波特
M·B·梅洛
T·北田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Massachusetts Institute of Technology
Original Assignee
Janssen Vaccines and Prevention BV
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines and Prevention BV, Massachusetts Institute of Technology filed Critical Janssen Vaccines and Prevention BV
Publication of CN111163799A publication Critical patent/CN111163799A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880063070.8A 2017-07-28 2018-07-27 用于异源repRNA免疫接种的方法和组合物 Pending CN111163799A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762538070P 2017-07-28 2017-07-28
US62/538,070 2017-07-28
US201762546259P 2017-08-16 2017-08-16
US62/546,259 2017-08-16
PCT/US2018/044075 WO2019023566A1 (en) 2017-07-28 2018-07-27 METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP

Publications (1)

Publication Number Publication Date
CN111163799A true CN111163799A (zh) 2020-05-15

Family

ID=63407511

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880063070.8A Pending CN111163799A (zh) 2017-07-28 2018-07-27 用于异源repRNA免疫接种的方法和组合物

Country Status (12)

Country Link
US (2) US11235051B2 (enExample)
EP (1) EP3658179B1 (enExample)
JP (1) JP7311489B2 (enExample)
KR (1) KR102806640B1 (enExample)
CN (1) CN111163799A (enExample)
AU (1) AU2018306614B2 (enExample)
BR (1) BR112020001052A2 (enExample)
CA (1) CA3071011A1 (enExample)
IL (1) IL272281B2 (enExample)
MA (1) MA49693A (enExample)
SG (1) SG11202000019RA (enExample)
WO (1) WO2019023566A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115232824A (zh) * 2021-04-22 2022-10-25 中国人民解放军军事科学院军事医学研究院 一种基于1083骨架的预防狂犬病毒感染的疫苗
CN116064597B (zh) * 2023-01-17 2024-04-26 北京大学 通过自主复制rna实现哺乳动物细胞中的定向进化和达尔文适应

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021006925A (es) * 2018-12-14 2021-07-07 Glaxosmithkline Biologicals Sa Composiciones y metodos heterologos de vacunacion con refuerzo inductor.
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US11026894B2 (en) 2019-01-10 2021-06-08 Massachusetts Institute Of Technology Lipid nanoparticles and use thereof to deliver RNA polynucleotides
PH12022551208A1 (en) 2019-11-18 2023-04-24 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
US11759515B2 (en) 2020-03-09 2023-09-19 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022036170A1 (en) 2020-08-14 2022-02-17 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
AU2022224967A1 (en) 2021-02-23 2023-07-27 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutation
AR125191A1 (es) 2021-03-22 2023-06-21 Lifeedit Therapeutics Inc Enzimas modificadoras del adn y sus fragmentos activos y variantes y métodos de uso
CN118119714A (zh) * 2021-09-02 2024-05-31 瑞普利科特生物科学公司 具有异源非结构蛋白的经修饰的甲病毒
WO2023156505A1 (en) 2022-02-17 2023-08-24 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103370411A (zh) * 2010-12-14 2013-10-23 美国卫生和人类服务部 腺病毒血清型26和血清型35线状病毒疫苗
CN103596586A (zh) * 2011-04-08 2014-02-19 免疫设计公司 免疫原性组合物及使用所述组合物诱导体液和细胞免疫反应的方法
US20140271714A1 (en) * 2013-03-15 2014-09-18 Monika Simmons Induction of an immune response against dengue virus using the prime-boost approach
WO2016187613A1 (en) * 2015-05-21 2016-11-24 Janssen Vaccines & Prevention B.V Methods and compositions for inducing protective immunity against filovirus infection and/or disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7285265B2 (en) 2002-04-25 2007-10-23 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
ATE447037T1 (de) 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
EP1687033A4 (en) 2003-11-12 2008-06-11 Us Navy IMPROVEMENT OF VACCINE-INDUCED IMMUNE REACTIONS AND PROTECTION THROUGH HETEROLOGY REINFORCEMENT WITH ALPHAVIRUS REPLICON VACCINE
DE602005017743D1 (de) 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
WO2008136845A2 (en) 2007-04-30 2008-11-13 Medtronic Minimed, Inc. Reservoir filling, bubble management, and infusion medium delivery systems and methods with same
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
KR101763093B1 (ko) 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
US20110300205A1 (en) 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
EP4218799A1 (en) * 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
HRP20161352T1 (hr) * 2010-07-06 2016-12-02 Glaxosmithkline Biologicals Sa Čestice nalik na virione za unos samoreplicirajućih molekula rna
EP2729168A2 (en) 2011-07-06 2014-05-14 Novartis AG Immunogenic compositions and uses thereof
IN2014KN02929A (enExample) * 2012-07-06 2015-05-08 Novartis Ag
AU2015311868B2 (en) * 2014-09-03 2018-11-22 Bavarian Nordic A/S Methods and compositions for enhancing immune responses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103370411A (zh) * 2010-12-14 2013-10-23 美国卫生和人类服务部 腺病毒血清型26和血清型35线状病毒疫苗
CN103596586A (zh) * 2011-04-08 2014-02-19 免疫设计公司 免疫原性组合物及使用所述组合物诱导体液和细胞免疫反应的方法
US20140271714A1 (en) * 2013-03-15 2014-09-18 Monika Simmons Induction of an immune response against dengue virus using the prime-boost approach
WO2016187613A1 (en) * 2015-05-21 2016-11-24 Janssen Vaccines & Prevention B.V Methods and compositions for inducing protective immunity against filovirus infection and/or disease

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115232824A (zh) * 2021-04-22 2022-10-25 中国人民解放军军事科学院军事医学研究院 一种基于1083骨架的预防狂犬病毒感染的疫苗
CN115232824B (zh) * 2021-04-22 2023-09-26 中国人民解放军军事科学院军事医学研究院 一种基于1083骨架的预防狂犬病毒感染的疫苗
CN116064597B (zh) * 2023-01-17 2024-04-26 北京大学 通过自主复制rna实现哺乳动物细胞中的定向进化和达尔文适应

Also Published As

Publication number Publication date
US20200230225A1 (en) 2020-07-23
JP2020528911A (ja) 2020-10-01
US20220111033A1 (en) 2022-04-14
AU2018306614A1 (en) 2020-01-30
US11235051B2 (en) 2022-02-01
KR102806640B1 (ko) 2025-05-12
KR20200037818A (ko) 2020-04-09
JP7311489B2 (ja) 2023-07-19
BR112020001052A2 (pt) 2020-09-08
AU2018306614B2 (en) 2024-08-29
US11964007B2 (en) 2024-04-23
IL272281B (en) 2022-12-01
WO2019023566A1 (en) 2019-01-31
IL272281A (en) 2020-03-31
MA49693A (fr) 2020-06-03
IL272281B2 (en) 2023-04-01
EP3658179A1 (en) 2020-06-03
CA3071011A1 (en) 2019-01-31
EP3658179B1 (en) 2025-09-17
EP3658179C0 (en) 2025-09-17
SG11202000019RA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
US11964007B2 (en) Methods and compositions for heterologous repRNA immunizations
Huang et al. COVID-19 mRNA vaccines
AU2003297039B2 (en) Multi-antigenic alphavirus replicon particles and methods
Capone et al. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials
AU2017297610B2 (en) Compositions and methods for alphavirus vaccination
CN101432291B (zh) 嵌合腺病毒载体
US11229692B2 (en) Methods and compositions for inducing protective immunity against RSV infection
WO2023086961A1 (en) Sars-cov-2 spike fused to a hepatitis b surface antigen
EP4351638A1 (en) Virus-like particle vaccine for coronavirus
Tang et al. Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer
EA043316B1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ГЕТЕРОЛОГИЧНЫХ репРНК ИММУНИЗАЦИЙ
EP4648781A1 (en) Recombinant modified sarna (vrp) for cancer vaccine
WO2018210871A1 (en) Methods and compositions for inducing protective immunity against rsv infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination